ST. LOUIS, MISSOURI – Avadel Pharmaceuticals, a dynamic biopharmaceutical company driven by a mission to transform medicines and improve lives, has placed Sarah Henson as their new Head of Talent & Organizational Development. Managing Partner, Tobin Anselmi and Recruiting Director, Kristen Perez led and placed the crucial HR search.
“Kristen and I are so pleased we had the opportunity to work with Angela and Avadel on this important addition to her HR Team. We are excited for both Sarah and Avadel and she joins the organization in this critical role,” shared Tobin Anselmi, Managing Partner at TCG.
In her newly created role, Sarah Henson will develop and execute a comprehensive talent management, organizational development and talent acquisition strategy aligning with Avadel’s core values and preparing them to scale. As the Head of Talent & Organizational Development, Sarah has a unique opportunity to put a thumbprint on a small but growing organization through the strategic direction, management, optimization, execution, and oversight of all Talent initiatives.
Sarah Henson brings a wealth of experience in talent strategy, organizational development, and learning & development to her new role at Avadel. With a career spanning leadership positions at Synapse Health, Louisiana-Pacific Corporation, and Unum, Sarah has successfully designed and implemented talent acquisition frameworks, leadership development programs, and performance management strategies that drive business success. She excels in building scalable talent infrastructures, fostering a culture of engagement, and aligning people strategies with organizational goals. Her passion for developing high-performing teams and enhancing employee experiences makes her a valuable addition to Avadel’s leadership team.
About Avadel Pharmaceuticals
Avadel Pharmaceuticals is a dynamic biopharmaceutical company driven by a mission to transform medicines and improve lives. They focus on innovative solutions that tackle the challenges patients face with current treatment options. One of the company’s key advancements is in the area of oxybate therapy, which is a widely used treatment for excessive daytime sleepiness (EDS) and cataplexy in individuals with narcolepsy. While traditional oxybate products require two nightly doses—one at bedtime and another in the middle of the night—Avadel has revolutionized this with their new therapy, LUMRYZ.
LUMRYZ, which received FDA approval on May 1, 2023, offers a once-nightly dose that eliminates the need for patients to wake up during the night for a second dose. This major improvement has earned LUMRYZ seven years of Orphan Drug Exclusivity from the FDA, and it is recognized as clinically superior to the previously available therapies.
What sets Avadel apart is its dedication to making a positive impact—not just for patients but also for their community and one another. Employees live the Avadel Values in everything they do, which is what makes working at Avadel a special experience.
About The Christopher Group
Through its award-winning, customized HR solutions, The Christopher Group (TCG) delivers critical human capital solutions in the area of executive HR search, interim HR leaders, fractional CHROs, and HR advisory and consulting. Since 1998, TCG has served clients across all industries, locations, company sizes, and verticals. Staffed by former HR professionals and highly trained search practitioners who have sat in the job, TCG has been named one of the Fastest-Growing, Best Non-Profit, Diversity, Private Equity, and Top 50 Executive Recruiting Firms by Hunt Scanlon as well as Forbes’ 2019, 2020, 2021 & 2022 list of America’s Best Executive Recruiting Firms.